PTAB to Review Novartis’ Patent on Regeneron Challenge

shot by IP News Shots / 7:19 pm on 27 October, 2021

Regeneron Pharmaceuticals, Inc. had challenged Novartis International AG’s patent alleging it to be invalid. The Patent Trial and Appeal Board (PTAB) has agreed to review the syringe patent by Novartis. The review board will take into account arguments from both the side. Regeneron is confident of winning the argument stating that at least a part of the patent is invalid and that “Novartis is unlawfully asserting an invalid patent.”

Industry: Pharmaceuticals | Type of IP: Litigations

Read more at Bloomberg Law